Interested in promotions? | Click here >>
5233
Human BAFF/TNFSF13B (hBAFF)
Cytokines
Growth Factors and Cytokines

Human BAFF/TNFSF13B (hBAFF) #5233

Citations (0)

We recommend the following alternatives

# Product Name Applications Reactivity
Human BAFF/TNFSF13B (hBAFF): Image 1
The proliferation of mouse splenic B cells treated with increasing concentrations of hBAFF in the presence of 10 μg/ml goat anti-mouse IgM μ chain was assessed. After 72 hour treatment with hBAFF, cells were incubated with a tetrazolium salt and the OD450-OD650 was determined.
Human BAFF/TNFSF13B (hBAFF): Image 2
The purity of recombinant hBAFF was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hBAFF and staining overnight with Coomassie Blue.

Formulation

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 10 mM DTT and 20 μg BSA per 1 μg hBAFF. Cystines are not required for bioactivity. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 10 mM DTT. Cystines are not required for bioactivity.

Storage

Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.
Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

Product Description

MW (kDa) 16
Purity >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hBAFF. All lots are greater than 98% pure.
Endotoxin Less than 0.01 ng endotoxin/1 μg hBAFF.
Activity The bioactivity of recombinant hBAFF was determined in a cell proliferation assay using mouse splenic B cells. The ED50 of each lot is between 0.5-2 ng/ml.
Molecular Formula Recombinant hBAFF contains no "tags" and the nonglycosylated protein has a calculated MW of 15,489. DTT-reduced and non-reduced protein migrate as 16 kDa polypeptides. The expected amino-terminal AVQGP of recombinant hBAFF was verified by amino acid sequencing.

Source / Purification

Recombinant human BAFF (hBAFF) Ala134-Leu285 (Accession #NP_006564) was expressed in human 293 cells at Cell Signaling Technology.

Background

BAFF, a member of the TNF superfamily of proteins, is a homotrimeric transmembrane protein, which is cleaved to produce a soluble cytokine (1). BAFF may also further oligomerize into 60-mer structures (1). BAFF is expressed by neutrophils, macrophages, dendritic cells, activated T cells, and epithelial cells (1,2). BAFF plays a key role in B cell development, survival, and activation (1,3,4). BAFF binds to three distinct receptors, BAFF-R, TACI, and BCMA (1). These receptors are differentially expressed during B cell development and among B cell subsets (1,2,4). While BAFF-R and BCMA bind to the homotrimeric form of BAFF, TACI only binds to membrane bound or higher order BAFF structures (1). The BAFF/ BAFF-R interaction activates both canonical and non-canonical NF-κB pathways, PI3K/Akt, and mTOR (2,4). Activation of the noncanonical NF-κB pathway via BAFF-R is negatively regulated by TRAF3 (5). Elevated levels of BAFF may exacerbate many autoimmune disorders, making it an attractive therapeutic target (2).
  1. Mackay, F. and Schneider, P. (2009) Nat Rev Immunol 9, 491-502.
  2. Moisini, I. and Davidson, A. (2009) Clin Exp Immunol 158, 155-63.
  3. Schiemann, B. et al. (2001) Science 293, 2111-4.
  4. Khan, W.N. (2009) J Immunol 183, 3561-7.
  5. Gardam, S. et al. (2008) Immunity 28, 391-401.

Pathways & Proteins

Explore pathways + proteins related to this product.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Inquiry Info.# 5233